
Reimbursement Top Challenge for Labs in 2025
ACLA president Susan Van Meter discusses some of the key issues labs faced in 2024, along with work to address these developments through 2025
ACLA president Susan Van Meter discusses some of the key issues labs faced in 2024, along with work to address these developments through 2025
Regulatory expert Julie Ballard shares her thoughts on the most useful resources for labs as they get ready to comply with Stage 1
Experts say new leadership could impact the cost and availability of IVDs as well as patients’ ability to afford lab testing
The EasyScreen assay received 510(k) clearance from the Food and Drug Administration earlier this year–but with a catch
Considerations for addressing compliance with Stage 1 of the FDA’s lab-developed tests final rule